Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 1, 2014
Pharmacy Choice - News - Over-the-Counter Drugs - October 1, 2014

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 18 of 18     Go To Page:

10/1/14 - BUYINS.NET: CNC, LII, MDRX Are Seasonally Ripe To Go Down In the Next Five Weeks
BUYINS.NET/ www.squeezetrigger.com is monitoring the Seasonality of CENTENE CORPORATION, LENNOX INTERNATIONAL INCORPORATED, Allscripts Healthcare Solutions Inc and each have a high seasonal probability to go Down in the next weeks. CNC CENTENE CORPORATION -2.43% 91.67% Wednesday, October 1st 2014. CENTENE CORPORATION- Centene Corporation provides..
10/1/14 - Researchers Submit Patent Application, "Dosage Form for Insertion into the Mouth", for Approval
By a News Reporter-Staff News Editor at Biotech Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Ryoo, Je Phil; Chu, Chun Kwong; Wang, Zheng, filed on May 16, 2014, was made available online on September 18, 2014. The patent's assignee is NAL Pharmaceuticals Ltd.. News editors obtained the following
9/30/14 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Data To Support Drug Product...
All comments should be identified with the OMB control number 0910-0695. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Testing of communication mess
9/30/14 - Sun Diagnostics, LLC Continues to Simplify Interference Testing with the Release of ASSURANCE? Drug Interference Test Kit
Manufacturers and clinical laboratories are doing a reasonably good job assessing endogenous interferents that may alter lab test results. Sun Diagnostics now offers ASSURANCE? DRUG Interference Test Kit for Laboratory Use as part of interference testing procedures. Drug components and concentrations are based on recommendations by the expert pan
9/29/14 - ?EastGate Acquisitions Enters Into A License Agreement With Purine Pharma, LLC For Marketing And Distribution Of Its Nutraceutical And Consumer Product Line
SALT LAKE CITY and TORONTO, Sept. 29, 2014/ PRNewswire/ EastGate Acquisitions Corporation, an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it has entered into a licensing agreement with Purine Phar
9/29/14 - Allergan Announces FDA Approves Revised Indication for OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema
Allergan, Inc., announced today that the U.S. Food and Drug Administration has approved OZURDEX 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema. Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved OZURDEX for use in the general DME patient
9/29/14 - Ethical Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Transparency Market Research includes new market research report "Positron Emission Tomography Market" to its huge collection of research reports.Albany, NY 09/29/2014 Ethical pharmaceuticals or prescription drugs are those licensed drugs that are regulated by various legislations to require a written medical prescription before it can be pro
9/29/14 - Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R) Ibuprofen
Flamel Technologies today announced the results of a First-in-Man clinical study in healthy volunteers using its proprietary LiquiTime drug delivery platform applied to ibuprofen, a broadly used medication for pain. The next step will be to move this product into a pivotal bioequivalence study in 2015, "said Mike Anderson, Chief Executive Office
9/29/14 - Lumara Health? to be Acquired in Two Separate Transactions for up to $1.107 Billion
AMAG Pharmaceuticals, Inc. will acquire Lumara Health, Inc. and its wholly owned subsidiaries, including its flagship product, Makena , for $675 million and additional contingent consideration of up to $350 million based on achievement of certain sales milestones. In a separate asset purchase transaction, a subsidiary of Perrigo Company plc will
9/29/14 - Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals
Perrigo Company plc announced today that it has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals. Under the terms of the agreement, Perrigo will receive an upfront payment in addition to multiple
9/29/14 - Perrigo Enters New Therapeutic Category With The Acquisition Of Women's Health Product Portfolio From Lumara Health
Perrigo Company plc announced today that it has signed a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri- based specialty pharmaceutical company, for $82 million in cash. Perrigo Chairman, President and CEO Joseph C. Papa stated, "I'm excited to announce
9/29/14 - SeeThruEquity Initiates Research Coverage on Innovus Pharmaceuticals, Inc. with a Target Price of $1.34
New York, NY/ ACCESSWIRE/ September 29, 2014/ SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Innovus Pharmaceuticals, Inc., an emerging pharmaceutical company engaged in the commercialization, licensing, and developme
9/27/14 - GNW-News: Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC (english)
Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia (TM) as their first ALK inhibitor for ALK+ NSCLC. Novartis International AG/ Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia (TM) as their first ALK inhibitor for ALK+ NSCLC. Processed and transmitted by NASDAQ O
9/27/14 - Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC
Novartis International AG/ Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia (TM) as their first ALK inhibitor for ALK+ NSCLC. *Longest median progression-free survival ever reported in this ALK+ non-small cell lung cancer patient population, most who received prior chemotherapy* Zykadia achieved overall..
9/26/14 - Patient-Focused Drug Development Public Meeting and Scientific Workshop on Female Sexual Dysfunction
At this meeting, FDA will obtain patients' perspectives on the impact that FSIAD has on their daily lives, as well as their perspectives on the available therapies for these conditions. The scientific workshop will take place on October 28, 2014, and will provide an opportunity for FDA to seek input from experts on scientific issues important to th
9/25/14 - FDA Chooses Four CPF Advocates to Speak on IPF Workshop Panel
DISTRICT OF COLUMBIA, Wash., Sept. 25, 2014 Four of the eight panelist to address the FDA tomorrow at the first U.S. Food and Drug Administration workshop on Idiopathic Pulmonary Fibrosis are on Capitol Hill today. The four, along with other 18 other advocates, are meeting with 38 congressional offices. Included in the group of FDA panelists are
9/25/14 - J.D. Power Reports: Pharmacists and Staff Play Increasingly Important Roles in Pharmacy Customer Satisfaction
Pharmacist and staff interactions with customers are increasingly important drivers of satisfaction and share of wallet for both brick and mortar as well as mail order pharmacies, while the speed of delivering and ease of ordering medication also drives satisfaction with mail order pharmacies, according to the J.D. Power 2014 U.S. Overall satisfa
9/24/14 - The Mentholatum Company Celebrates Its 125th Anniversary
The Mentholatum Company was founded in 1889 in Wichita, Kansas by Mr. Since 1889, The Mentholatum Company has grown and prospered from a small purveyor of soaps and toiletries into an international company, marketing quality proprietary non-prescription pharmaceuticals and skincare products around the world. While family owned for 99 years, the com
Articles(s): 1 - 18 of 18     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415